Strictly Embargoed for 07.00 on 28 July 2016

TyraTech, Inc.

("TyraTech" or the "Company")

Pre Close Trading Update

TyraTech, Inc. (AIM: TYR and TYRU), a life sciences technology company focused on nature-derived insect and parasite control products gives the following update on trading ahead of the announcement of its half year results to 30 June 2016.

The Company's trading performance in the first half continues the upward trend from prior periods, with unit sales of the Vamousse[®] head lice product line continuing to progress and operating expense efficiencies now being realised. These trends are anticipated to continue throughout the second half. The Board expects the net loss over the year to remain in line with current market expectations.

Vamousse

Unit sales of Vamousse were in line with expectations, showing strong growth over the corresponding period for 2015 across all geographies and customers. Vamousse continues to establish itself as a leading brand and is performing well in the market against competitor products, gaining market share.

Revenues associated with these sales have been modestly impacted by currency translation effects on UK sales and by revenue recognition factors, due to sale or return associated with one new US customer. These impacts are expected to continue through the rest of the year.

PureScience™

The PureScience portfolio of animal health products is showing good results in field and customer trials, and three products were launched for poultry and swine production at the end of the half.

The roll-out of PureScience in the first half was slower than anticipated mainly due to the time of completing the field trials and it is now expected that the revenue impact will be in the second half of the year.

The Company expects to announce its interim results in mid-September 2016 and will give a further update at that time.

-ends-

For further information please visit: <u>www.tyratech.com</u> or contact:

TyraTech Inc.	
Bruno Jactel, Chief Executive Officer	Tel: +1 919 415 4340
Erica Boisvert, Chief Financial Officer	Tel: +1 919 415 4287
SPARK Advisory Partners Limited (Nominated Adviser)	
Matt Davis / Mark Brady	Tel: +44 20 3368 3551
Allenby Capital Limited (Joint Broker)	
Chris Crawford	Tel: +44 20 3328 5656

Whitman Howard Limited (Joint Broker)

Ranald McGregor-Smith

Belvedere Communications (PR)

John West / Kim van Beeck

Tel: +44 20 7659 1250

Tel: +44 20 3567 0510